Since its discovery in 1999, a number of studies have evaluated the role of Nox1 NADPH oxidase in the cardiovascular system. Nox1 is activated in vascular cells in response to several different agonists, with its activity regulated at the transcriptional level as well as by NADPH oxidase complex formation, protein stabilization and post-translational modification. Nox1 has been shown to decrease the bioavailability of nitric oxide, transactivate the epidermal growth factor receptor, induce pro-inflammatory signalling, and promote cell migration and proliferation. Enhanced expression and activity of Nox1 under pathologic conditions results in excessive production of reactive oxygen species and dysregulated cellular function. Indeed, studies using genetic models of Nox1 deficiency or overexpression have revealed roles for Nox1 in the pathogenesis of cardiovascular diseases ranging from atherosclerosis to hypertension, restenosis and ischaemia/reperfusion injury. These data suggest that Nox1 is a potential therapeutic target for vascular disease, and drug development efforts are ongoing to identify a specific bioavailable inhibitor of Nox1.
Skip Nav Destination
Article navigation
February 2016
-
Cover Image
Cover Image
Image modified from a figure representing the 5 mechanisms of annexin A1 externalization through non-classic secretory pathways, discussed by Boudhraa et al in issue 130(4) of Clinical Science. For further details please see pp. 205–220. Image kindly provided by Z. Boudhraa, B. Bouchon, C. Viallard, M. D'Incan and F. Degoul.
Review Article|
December 17 2015
Nox1 in cardiovascular diseases: regulation and pathophysiology
Marcela Gimenez;
Marcela Gimenez
*Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, U.S.A.
†Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
Search for other works by this author on:
Brandon M. Schickling;
Brandon M. Schickling
*Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, U.S.A.
Search for other works by this author on:
Lucia R. Lopes;
Lucia R. Lopes
†Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
Search for other works by this author on:
Francis J. Miller, Jr
*Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, U.S.A.
‡Veterans Affairs Medical Center of Iowa City, Iowa City, IA 52246, U.S.A.
Correspondence: Professor Francis J. Miller, Jr (email francis-miller@uiowa.edu).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
June 04 2015
Revision Received:
October 05 2015
Accepted:
October 06 2015
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2016 Authors; published by Portland Press Limited
2016
Clin Sci (Lond) (2016) 130 (3): 151–165.
Article history
Received:
June 04 2015
Revision Received:
October 05 2015
Accepted:
October 06 2015
Citation
Marcela Gimenez, Brandon M. Schickling, Lucia R. Lopes, Francis J. Miller; Nox1 in cardiovascular diseases: regulation and pathophysiology. Clin Sci (Lond) 1 February 2016; 130 (3): 151–165. doi: https://doi.org/10.1042/CS20150404
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.